Blog
Keep up to date with the latest news from Instem.
Accelerating Non-GLP Drug Discovery with BioRails
From preparation to analysis and reporting, BioRails actively supports the entire experimental workflow.
Why QC Laboratories Can’t Afford Blind Spots in Their File Systems
FDA Form 483 observations related to data integrity remain a persistent issue for the industry, and the consequences for a lab are significant.
Instem Interact 2026 – A Resounding Success
Turning Insight into Innovation in Preclinical R&D
Leadscope Model Applier™ v2026 – Expanding confidence in predictive toxicology
This release introduces advanced predictive models and extensive toxicological data to support rigorous chemical safety assessments.
What the FDA Webcast Revealed About SEND (and Why It Matters)
“For the first time, the FDA openly acknowledged that they are rejecting some SEND datasets because the quality isn’t good enough. No ambiguity. Just a clear statement that quality matters, and that poor SEND has...
d-wise Appoints 2x-CEO, ex-Labcorp Head of Software Solutions to Drive Next Phase of Strategy & Growth
BOSTON, USA – 21 April 2026: d-wise (an Instem company), a leader in statistical computing infrastructure and clinical trial transparency, today announced the appointment of Christine Oliver as its President. Christine brings over two decades...
Instem Taps ex-Novartis Head of Emerging Technologies to Put Science Behind Practical AI and NAMs
Instem, a leading provider of SaaS solutions for preclinical R&D, today announced the appointment of Szczepan Baran, VMD, MS, as Chief Scientific Officer. In the role, Szczepan will lead scientific and AI strategy across in...
The Journey of a Molecule – IND Package Preparation
Complete, Compliant, and SEND‑Ready Submissions for Regulatory Success
Enhancing Reporting, Telemetry, and Signal Processing for Physiological Research with NOTOCORD-hem 5.2
Targeted enhancements across the entire physiological workflow, from acquisition to analysis to Excel-based reporting.
